ImmunityBio, Inc. clinical trial pipeline

3 trials changed in the last 30 days: 0 stopped, 3 with notable changes, 0 with minor changes only.

1. Notable

   NAI Plus Standard of Care Compared With Placebo Plus Standard of…NAI Plus Standard of Care Compared With Placebo Plus Standard of Care · Sepsis

   Primary completion pushed from Oct 12, 2027 to May 12, 2028

   Also in this update: Primary endpoint(s) modified; Phase changed: Phase 1/2 → Phase 2

   ImmunityBio, Inc.·Phase 2· NCT07783789· Registry history of NCT07783789 on ClinicalTrials.gov (opens the registry)

   Updated Sep 25, 2026

2. Notable

   Anktiva · COVID-19

   Primary and study completion pushed from Jul 2026 to Mar 2027

   ImmunityBio, Inc.·Phase 2· NCT07123727· Registry history of NCT07123727 on ClinicalTrials.gov (opens the registry)

   Updated Sep 24, 2026

3. Notable

   N-803 in Combination With Pembrolizumab and Enfortumab Vedotin…N-803 in Combination With Pembrolizumab and Enfortumab Vedotin · Urothelial Cancer

   Trial status changed: Withdrawn → Not Yet Recruiting

   ImmunityBio, Inc.·Phase 1· NCT07217496· Registry history of NCT07217496 on ClinicalTrials.gov (opens the registry)

   Updated Sep 24, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.